Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://www.journalmc.org

Case Report

Volume 12, Number 10, October 2021, pages 424-428


Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis

Tables

Table 1. Basic Labs of the Patient
 
VariablesDay 1Day 5Day 9Day 13Day of discharge
WBC: white blood cell; NV: normal value; BUN: blood urea nitrogen; N/A: not applicable.
WBC (NV: 4.1 - 11.0 × 103/µL)10.65.19.95.56.9
Neutrophils (NV: 2.1 - 8.4 × 103/µL)8.84.48.44.25.1
Hemoglobin (NV: 12.0 - 16.0 g/dL)8.07.77.58.611.2
Platelet (NV: 150 - 400 × 103/µL)1308982109115
BUN (NV: 8 - 24 mg/dL)3025605148
Creatinine (NV: 0.55 - 1.30 mg/dL)1.140.920.860.780.65
Fibrinogen (NV: 200 - 400 mg/dL)N/A165171203199
Arterial blood pH (NV: 7.38 - 7.42)7.427.407.477.47N/A

 

Table 2. Autoimmune Comprehensive Neurology Antibody Panels
 
Results
Titin antibody (reference: < 11 SI)91
Striated muscle antibodyPositive
Striated muscle antibody titer (reference: < 1:40)1:160
Acetylcholine receptor modulating antibody (reference: < 32% inhibition)< 6%
Acetylcholine receptor blocking antibody (reference: < 15% inhibition)< 15%
Acetylcholine receptor binding antibody< 0.30
  Negative: ≤ 0.30 nmol/L
  Equivocal: 0.31 - 0.49 nmol/L
  Positive: ≥ 0.50 nmol/L
Autoimmune comprehensive neurology antibody panelNegative